"Through our partnership with Asahi, we are pleased to offer physicians a new option for treating challenging lesions," said David Van Meter, general manager, Coronary Technologies, Abbott Vascular. "The Tornus complements Abbott's broad line of Asahi guidewires, as well as our rapidly growing portfolio of devices for vascular interventionalists. These outstanding tools have earned high marks from the physicians who rely on them to deliver life-saving devices to patients with known areas of vessel disease."

The Tornus is manufactured by Japan-based Asahi Intecc Co., Ltd. Abbott has a licensing agreement with Asahi Intecc to distribute its guidewires in the U.S. and certain countries worldwide.


About Chronic Occlusions
Compared with areas of vessel narrowing (stenoses), chronic occlusions are typically longer and contain larger, denser masses of plaque. Chronic occlusions are generally characterized by dense, fibrous tissue that is often partially calcified and difficult to penetrate with conventional interventional technology tools. The severity of a chronic occlusion is determined by the degree of vessel narrowing, the rate of blood flow through the narrowing, and the age (chronicity) of the occlusion. Research reveals that approximately 30 percent of patients with coronary artery disease have at least one chronic occlusion.

About Abbott Vascular
Abbott Vascular, a division of Abbott, is transforming the treatment of vascular disease, combining the latest medical device innovations with world-class pharmaceuticals to advance medicine and improve patient care. Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety, effectiveness and ease of use in treating patients with vascular disease. Abbott Vascular is headquartered in Redwood City, Calif. For more information on Abbott Vascular, visit http://www.abbottvascular.com.

About Abbott
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 60,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

SOURCE Abbott
Web Site: http://www.abbott.com http://www.abbottvascular.com

Back to HCB News

More Voices